Parthenolide, a sesquiterpene lactone from the medical herb feverfew, shows anticancer activity against human melanoma cells in vitro

Melanoma Research

Volumn 20, Issue 1, 2010, Pages 21-34

  Lesiak, Karolina ^a   Koprowska, Kamila ^a   Zalesna, Izabela ^a   Nejc, Dariusz ^a   Düchler, Markus ^a,b   Czyz, Malgorzata ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b Foetal Maternal Dept   (Poland)

Author keywords

Caspase 3; Cell death; Melanoma; Michael adduct formation; Mitochondrial depolarization; Parthenolide

Indexed keywords

ACETYLCYSTEINE; ASCORBIC ACID; CASPASE 3; PARTHENOLIDE; REACTIVE OXYGEN METABOLITE; TETRAZOLIUM;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL ADHESION; CELL DEATH; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ANTAGONISM; ENZYME ACTIVATION; ENZYME ACTIVITY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MALE; MELANOCYTE; MELANOMA CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; PRIORITY JOURNAL; SKIN BIOPSY;

ACETYLCYSTEINE; ADULT; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASE 3; CELL ADHESION; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DRUG INTERACTIONS; FEMALE; FLOW CYTOMETRY; HUMANS; MALE; MELANOMA; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICE; MIDDLE AGED; REACTIVE OXYGEN SPECIES; SESQUITERPENES; SKIN NEOPLASMS; TANACETUM PARTHENIUM;

EID: 75749144323     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/CMR.0b013e328333bbe4     Document Type: Article

References (56)

1. Gray-Schopfer V, Wellbrock C, Marais R. Melanoma biology and new targeted therapy. Nature 2007; 445:851-857.
2. Fecher LA, Cummings SD, Keefe MJ, Alani RM. Toward a molecular classification of melanoma. J Clin Oncol 2007; 25:1606-1620.
3. Dhawan P, Richmond A. A novel NF-kappa B-inducing kinase-MAPK signaling pathway up-regulates NF-kappa B activity in melanoma cells. J Biol Chem 2002; 277:7920-7928.
4. Ueda Y, Richmond A. NF-kappa B activation in melanoma. Pigment Cell Res 2006; 19:112-124.
5. Govindarajan B, Sligh JE, Vincent BJ, Li M, Canter JA, Nickoloff BJ, et al. Overexpression of Akt converts radial growth melanoma to vertical growth melanoma. J Clin Invest 2007; 117:719-729.
6. Liu ZJ, Xiao M, Balint K, Smalley KS, Brafford P, Qiu R, et al. Notch1 signaling promotes primary melanoma progression by activating mitogen-activated protein kinase/phosphatidylinositol 3-kinase-Akt pathways and up-regulating N-cadherin expression. Cancer Res 2006; 66:4182-4190.
7. Dankort D, Curley DP, Cartlidge RA, Nelson B, Karnezis AN, Damsky WE Jr, et al. Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet 2009; 41:544-552.
8. Smalley KSM, Haass NK, Brafford PA, Lioni M, Flaherty KT, Herlyn M. Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol Cancer Ther 2006; 5:1136-1144.
9. Hoek K, Rimm DL, Williams KR, Zhao H, Ariyan S, Lin A, et al. Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas. Cancer Res 2004; 64:5270-5282.
10. Balint K, Xiao M, Pinnix CC, Soma A, Veres I, Juhasz I, et al. Activation of Notch1 signaling is required for b-catenin-mediated human primary melanoma progression. J Clin Invest 2005; 115:3166-3176.
11. Liu Y, Tao J, Li Y, Yang J, Yu Y, Wang M, et al. Targeting hypoxia-inducible factor-1alpha with Tf-PEI-shRNA complex via transferrin receptor-mediated endocytosis inhibits melanoma growth. Mol Ther 2009; 17:269-277.
12. Melnikova VO, Bar-Eli M. Transcriptional control of the melanoma malignant phenotype. Cancer Biol Ther 2008; 7:997-1003.
13. Hassel JC, Winnemöller D, Schartl M, Wellbrock C. STAT5 contributes to antiapoptosis in melanoma. Melanoma Res 2008; 18:378-385.
14. Kuphal S, Palm HG, Poser I, Bosserhoff AK. Snail-regulated genes in malignant melanoma. Melanoma Res 2005; 15:305-313.
15. Pozarowski P, Halicka DH, Darzynkiewicz Z. NF-kB inhibitor sespuiterpene parthenolide induces concurrently atypical apoptosis and cell necrosis: difficulties in identification of dead cells in such cultures. Cytometry 2003; 54A:118-124.
16. Wen J, You KR, Lee SY, Song CH, Kim DG. Oxidative stress-mediated apoptosis. The anticancer effect of the sesquiterpene lactone parthenolide. J Biol Chem 2002; 277:38954-38964.
17. Guzman ML, Rossi RM, Karnischky L, Li X, Peterson DR, Howard DS, et al. The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood 2005; 105:4163-4169.
18. Anderson KN, Bejcek BE. Parthenolide induces apoptosis in glioblastomas without affecting NF-kappa B. J Pharmacol Sci 2008; 106:318-320.
19. Wang W, Adachi M, Kawamura R, Sakamoto H, Hayashi T, Ishida T, et al. Parthenolide-induced apoptosis in multiple myeloma cells involves reactive oxygen species generation and cell sensitivity depends on catalase activity. Apoptosis 2006; 11:2225-2235.
20. Zhang S, Ong CN, Shen HM. Critical roles of intracellular thiols and calcium in parthenolide-induced apoptosis in human colorectal cancer cells. Cancer Lett 2004; 208:143-153.
21. Steele AJ, Jones DT, Ganeshaguru K, Duke VM, Yogashangary BC, North JM, et al. The sesquiterpene lactone parthenolide induces selective apoptosis of B-chronic lymphocytic leukemia cells in vitro. Leukemia 2006; 20:1073-1079.
22. Zunino SJ, Ducore JM, Storms DH. Parthenolide induces significant apoptosis and production of reactive oxygen species in high-risk pre-B leukemia cells. Cancer Lett 2007; 254:119-127.
23. Kwok BH, Koh B, Ndubuisi MI, Elofsson M, Crews CM. The antiinflammatory natural product parthenolide from the medicinal herb feverfew directly binds to and inhibits I kappa B kinase. Chem Biol 2001; 8:759-766.
24. Mendonca MS, Chin-Sinex H, Gomez-Millan J, Datzman N, Hardacre M, Comerford K, et al. Parthenolide sensitizes cells to X-ray-induced cell killing through inhibition of NF-kappa B and split-dose repair. Radiat Res 2007; 168:689-697.
25. Hehner SP, Heinrich M, Bork PM, Vogt M, Ratter F, Lehmann V, et al. Sesquiterpene lactones specifically inhibit activation of NF-kappa B by preventing the degradation of I kappa B-alpha and I kappa B-beta. J Biol Chem 1998; 273:1288-1297.
26. Gopal YN, Chanchorn E, Van Dyke MW. Parthenolide promotes the ubiquitination of MDM2 and activates p53 cellular functions. Mol Cancer Ther 2009; 8:552-562.
27. Liu Z, Liu S, Xie Z, Pavlovicz RE, Wu J, Chen P, et al. Modulation of DNA methylation by a sesquiterpene lactone Parthenolide. J Pharmacol Exp Ther 2009; 329:505-514.
28. Straume O, Smeds J, Kumar R, Hemminki K, Akslen LA. Significant impact of promoter hypermethylation and the 540 C> T polymorphism of CDKN2A in cutaneous melanoma of the vertical growth phase. Am J Pathol 2002; 161:229-237.
29. Marini A, Mirmohammadsadegh A, Nambiar S, Gustrau A, Ruzicka T, Hengge UR. Epigenetic inactivation of tumor suppressor genes in serum of patients with cutaneous melanoma. J Invest Dermatol 2006; 126:422-431.
30. Polsky D, Bastian BC, Hazan C, Melzer K, Pack J, Houghton A, et al. HDM2 protein overexpression, but not gene amplification, is related to tumorigenesis of cutaneous melanoma. Cancer Res 2001; 61:7642-7646.
31. Guzman ML, Rossi RM, Neelakantan S, Li X, Corbett CA, Hassane DC, et al. An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood 2007; 110:4427-4435.
32. Kawasaki BT, Hurt EM, Kalathur M, Duhagon MA, Milner JA, Kim YS, et al. Effects of the sesquiterpene lactone parthenolide on prostate tumorinitiating cells: an integrated molecular profiling approach. Prostate 2009; 69:827-837.
33. Zhou J, Zhang H, Gu P, Bai J, Margolick JB, Zhang Y. NF-kappa B pathway inhibitors preferentially inhibit breast cancer stem-like cells. Breast Cancer Res Treat 2008; 111:419-427.
34. Fang D, Nguyen TK, Leishear K, Finko R, Kulp AN, Hotz S, et al. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res 2005; 65:9328-9337.
35. Grichnik JM, Burch JA, Schulteis RD, Shan S, Liu J, Darrow TL, et al. Melanoma, a tumor based on a mutant stem cell? J Invest Derm 2006; 126:142-153.
36. Verhaegen M, Bauer JA, Martín de la Vega C, Wang G, Wolter KG, Brenner JC, et al. A novel BH3 mimetic reveals a mitogen-activated protein kinase-dependent mechanism of melanoma cell death controlled by p53 and reactive oxygen species. Cancer Res 2006; 66:11348-11359.
37. Düchler M, Stepnik M. Cytotoxic effects of a combination of three natural compounds to leukemia cells in vitro. Cancer Ther 2008; 6:733-740.
38. Parada-Turska J, Paduch R, Majdan M, Kandefer-Szerszeñ M, Rzeski W. Antiproliferative activity of parthenolide against three human cancer cell lines and human umbilical vein endothelial cells. Pharmacol Rep 2007; 59:233-237.
39. Oka D, Nishimura K, Shiba M, Nakai Y, Arai Y, Nakayama M, et al. Sesquiterpene lactone parthenolide suppresses tumor growth in a xenograft model of renal cell carcinoma by inhibiting the activation of NF-kappa B. Int J Cancer 2007; 120:2576-2581.
40. Wu C, Chen F, Rushing JW, Wang X, Kim HJ, Huang G, et al. Antiproliferative activities of parthenolide and golden feverfew extract against three human cancer cell lines. J Med Food 2006; 9:55-61.
41. Murphy JJ, Heptinstall S, Mitchell JR. Randomised double-blind placebocontrolled trial of feverfew in migraine prevention. Lancet 1988; 2:189-192.
42. Curry EA 3rd, Murry DJ, Yoder C, Fife K, Armstrong V, Nakshatri H, et al. Phase I dose escalation trial of feverfew with standardized doses of parthenolide in patients with cancer. Invest New Drugs 2004; 22:299-305.
43. Kishida Y, Yoshikawa H, Myoui A. Parthenolide, a natural inhibitor of nuclear factor-kappa B, inhibits lung colonization of murine osteosarcoma cells. Clin Cancer Res 2007; 13:59-67.
44. Nakshatri H, Rice SE, Bhat-Nakshatri P. Antitumor agent parthenolide reverses resistance of breast cancer cells to tumor necrosis factor-related apoptosis-inducing ligand through sustained activation of c-Jun N-terminal kinase. Oncogene 2004; 23:7330-7344.
45. Michard Q, Jaouen G, Vessieres A, Bernard BA. Evaluation of cytotoxic properties of organometallic ferrocifens on melanocytes, primary and metastatic melanoma cell lines. J Inorg Biochem 2008; 102:1980-1985.
46. Wittgen HG, van Kempen LC. Reactive oxygen species in melanoma and its therapeutic implications. Melanoma Res 2007; 17:400-409.
47. Meyskens FL, McNulty SE, Buckmeier JA, Tohidian NB, Spillane TJ, Kahlon RS, et al. Aberrant redox regulation in human metastatic melanoma cells compared to normal melanocytes. Free Rad Biol Med 2001; 31:799-808.
48. Meyskens FL Jr, Farmer P, Fruehauf JP. Redox regulation in human melanocytes and melanoma. Pigment Cell Res 2001; 14:148-154.
49. Gillissen A, Nowak D. Characterization of N-acetylcysteine and ambroxol in anti-oxidant therapy. Respir Med 1998; 92:609-623.
50. Zhang S, Won YK, Ong CN, Shen HM. Anti-cancer potential of sesquiterpene lactones: bioactivity and molecular mechanisms. Curr Med Chem Anticancer Agents 2005; 5:239-249.
51. Cabello CM, Bair WB 3rd, Lamore SD, Ley S, Bause AS, Azimian S, et al. The cinnamon-derived Michael acceptor cinnamic aldehyde impairs melanoma cell proliferation, invasiveness, and tumor growth. Free Radic Biol Med 2009; 46:220-231.
52. Rozenblat S, Grossman S, Bergman M, Gottlieb H, Cohen Y, Dovrat S. Induction of G2/M arrest and apoptosis by sesquiterpene lactones in human melanoma cell lines. Biochem Pharmacol 2008; 75:369-382.
53. Wang X, Thomas B, Sachdeva R, Arterburn L, Frye L, Hatcher PG, et al. Mechanism of arylating quinone toxicity involving Michael adduct formation and induction of endoplasmic reticulum stress. Proc Natl Acad Sci U S A 2006; 103:3604-3609.
54. Yang J, Zaja-Milatovic S, Thu YM, Lee F, Smykla R, Richmond A. Molecular determinants of melanoma malignancy: selecting targets for improved efficacy of chemotherapy. Mol Cancer Ther 2009; 8:636-647.
55. Schön M, Wienrich BG, Kneitz S, Sennefelder H, Amschler K, Vöhringer V, et al. KINK-1, a novel small-molecule inhibitor of IKKbeta, and the susceptibility of melanoma cells to antitumoral treatment. J Natl Cancer Inst 2008; 100:862-875.
56. Reu FJ, Bae SI, Cherkassky L, Leaman DW, Lindner D, Beaulieu N, et al. Overcoming resistance to interferon-induced apoptosis of renal carcinoma and melanoma cells by DNA demethylation. J Clin Oncol 2006; 24:3771-3779.